Published Date : May 22, 2017
ALBANY, New York, May 22, 2017: MarketResearchReports.biz in its new market study titled “Rheumatoid Arthritis Therapeutics In South-East Asia Markets To 2022 - Novel JAK And IL-6 Receptor Inhibitors To Stimulate Moderate Growth Despite Launch Of Biosimilars Of Blockbuster Anti-TNFs.” According to the report, the South-East Asia RA therapeutics market is expected to rise from US$1.04 bn in 2015 to U$1.4 bn by 2022, expanding at a CAGR of 4.7% between 2015 and 2022.
The report studies rheumatoid arthritis (RA), its causes, prevention measures, and treatment options. The key factors driving the market in South-East Asia and those, which impede the growth of the market have been discussed in detail. The key segments of the market are studied and so are the sub-segments. The leading, declining, and most promising segments are pointed out. The treatment to cure RA is presently unavailable and thus, there is a vast scope of development in the market. Players have the opportunity to meet the unmet medical needs of patients suffering from rheumatoid arthritis. Thus, there is a huge potential for growth in this market.
Rheumatoid Arthritis (RA) progressively affects the joints and causes gradual bone erosion over the years. The diseases results in pain and stiffness, primarily in the hand and feet area. This can often hamper mobility and thus, needs treatment or could result in total destruction of the joints and cause disability. All these factors are boosting the rheumatoid arthritis therapeutics market. Since the disease is chronic, it requires consistent treatment, driving the demand for rheumatoid arthritis therapeutics, despite resulting in a very high annual cost of therapy. The approval of new drugs in the market is encouraging the growth of the market and also leading to increased competition among players.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/1068036
As per the report, TNF inhibitors are leading in the rheumatoid arthritis therapeutics market, for those patients not showing effective results to traditional disease-modifying anti-rheumatic drugs (DMARD). Also available are targeted programs such as Janus kinase (JAK) inhibitor Xeljanz, which can replace ineffective TNF inhibitors. Patients suffering from RA are susceptible to risks involving cardiac diseases. However, studies have shown that Xeljanz significantly reduces the risk of cardiac diseases. Although these therapies are superior than conventional DMARD therapies, there remains a wide scope for enhancing the safety of therapeutics. There have been increasing cases of infections from frequent immunosuppression. Thus, these therapies become risky for patients vulnerable to infections, posing a challenge for the market.
There is a need to create biologics which make use of minimally invasive drug delivery methods and are convenient. As most therapies are intravenously or subcutaneously administered, they cause pain, rashes, and allergic reactions at the infusion or injection site. They may also cause, chills, fever, nausea, and headache. Hence, there exists the unmet need for therapies that are convenient and can be administered safely without reactions and side effects.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org